Brise Pharmaceutical (Shanghai) Co. Ltd. has discovered carbocyclic or heterocyclic derivatives acting as transient receptor potential cation channel subfamily M member 3 (TRPM3) antagonists.

Apmonia Therapeutics SAS, the Centre National de la Recherche Scientifique and the Université de Reims Champagne Ardenne have disclosed LRP1-derived polypeptides acting as cathepsin D (CTSD) inhibitors.

Sanofi SA and UCB SA have jointly reported active metabolites of balinatunfib acting as TNF-α modulators.

Work at Emcure Pharmaceuticals Ltd. and Peptris Technologies has led to the identification of new fused bicyclic heterocyclic derivatives acting as histone deacetylase (HDAC) inhibitors.

Bayer AG has synthesized new son of sevenless homolog 1 (SOS1) inhibitors reported to useful for the treatment of cancer.

Shanghai Fudan Zhangjiang Biopharmaceutical Co. Ltd. has discovered anthracycline compounds potentially useful for the treatment of cancer.

Beijing Konruns Pharmaceutical Co. Ltd. has patented new transforming acidic coiled-coil-containing protein (TACC) inhibitors described as potentially useful for the treatment of cancer.

Genfleet Therapeutics (Shanghai) Co. Ltd. has identified new acryloyl compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors.

Hangzhou Innogate Pharma Co. Ltd. has reported cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors. They are described as useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis, myocardial infarction and Parkinson’s disease, among others.

Chong Kun Dang Pharmaceutical Corp. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors designed for use in the treatment of cancer and inflammatory disorders.